Physicians treating patients with platinum-sensitive ovarian cancer can choose from a range of therapies, including doublet chemotherapy with or without bevacizumab (Avastin) and PARP inhibitors.
Jason Harris
Advertisement
Articles by Jason Harris
Merck filed the supplemental biologics license application based on results from the phase II KEYNOTE-158 trial.
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) compared with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).
HPV vaccination is currently indicated for the prevention of cervical, vulvar, and vaginal cancers in women, and anal cancers in both women and men.
Advertisement
Latest Updated Articles
HPV Vaccine Reduces High-Risk Infections, But Are People Getting Vaccinated?Published: June 4th 2017 | Updated:
First-Line Combo Immunotherapy Improves PFS in High TMB Non-Small Cell Lung CancerPublished: February 5th 2018 | Updated:
Keytruda Granted Priority Review in Cervical CancerPublished: March 15th 2018 | Updated:
Examining Treatment Strategies in in Platinum-Sensitive Ovarian CancerPublished: February 13th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
3
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
4
Doxecitine–Doxribtimine Becomes First Approved Treatment for Rare Genetic Disorder
5
